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Abstract
Cardiovascular disease (CVD) risk factors can be classed as modifiable or non-modifiable. 
Physical inactivity and obesity represent major behavioural risk factors for the initiation, 
development and progression of CVD. Platelet dysfunction is pivotal to the aetiology of 
CVD, a chronic vascular inflammatory condition, which is characterised by a lag time 
between onset and clinical manifestation. This indicates the role of epigenetic drift, defined 
by stochastic patterns of gene expression not dependent on dynamic changes in coding 
DNA. The epigenome, a collection of chemical marks on DNA and histones, is established 
during embryogenesis and modified by age and lifestyle. Biogenesis and effector function 
of non-coding RNA, such as microRNA, play a regulatory role in gene expression and 
thus the epigenetic mechanism. In this chapter, we will focus on the effect of the modifi-
able risk factors of physical activity/inactivity and overweight/obesity on platelet function, 
via epigenetic changes in both megakaryocytopoiesis and thrombopoiesis. We will also discuss 
the role of acute exercise on platelet function and the impact of cardiorespiratory fitness 
(CRF) on platelet responses to acute exercise. This chapter will highlight the potential role 
of platelets as circulating functional biomarkers of epigenetic drift to implement, optimise 
and monitor CVD preventive management strategies.
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1. Introduction
1.1. Epigenetics
Epigenetics describes modifiable changes that occur to genes, via chemical modifications 
and/or varying states of chromatin organisation and structure, which alter the gene expres-
sion without altering the DNA sequence itself. Smoking habits, obesity, ageing and physi-
cal fitness among others are examples of environmental factors that have been suggested to 
have a long-term influence on epigenetic changes [1]. Epigenetics may be classed as three 
distinct but highly interconnected processes; DNA methylation, histone modification and 
RNA-associated silencing (Figure 1). DNA methylation and histone modification alter DNA 
accessibility for transcriptional machinery and chromatin structure. These changes are heri-
table and can be passed down between generations through either mitosis or meiosis. DNA 
methylation involves the addition of a methyl group to the 5-position of cytosine by DNA 
methyl-transferases, at areas known as CpG islands. Methyl groups control gene expression 
by binding to promoter sites of the gene. This changes the affinity of methylation-sensitive 
binding proteins, and is associated with transcriptional gene silencing [2]. Whilst required 
for normal development, changes in DNA methylation have been linked to CVD conditions 
such as atherosclerosis. For example, the athero-protective oestrogen receptor genes ESR1 
and ESR2, usually expressed in SMCs, are hyper-methylated in atherosclerosis [3, 4].
Unlike the platelet transcriptome and proteome, the investigation of epigenetic processes is 
an almost completely unexplored area in platelet biology, as analysis of these mechanisms 
requires DNA [2]. Although anucleate, platelets have functionally active mitochondria, 
with mitochondrial DNA (mtDNA) that can also be methylated, moderating the control of 
mitochondrial gene expression. Interestingly, Zhong and colleagues recently reported that 
de novo DNA synthesis in mitochondria, and its subsequent oxidation, plays a key role in trig-
gering the innate immune response. Mitochondria can regulate how immune cells respond 
to infection and tissue damage, producing pro- or anti-inflammatory signals by regulating 
Krebs cycle metabolites or the production of reactive oxygen species (ROS). More and more 
examples are being found of mitochondrial functions being repurposed in unexpected ways 
to contribute to many biological processes, including inflammatory signalling [5].
Understanding epigenetic regulation of mitochondrial genes in platelets is proving crucial to 
understanding their implication in CVD development. Novel research by Baccarelli and Byun 
showed that CVD patients had significantly higher platelet mtDNA methylation than healthy 
individuals in MT-CO1, MT-C02, MT-CO3 and MT-TL1 genes involved in ATP synthesis [6]. 
These results suggest that DNA methylation in platelet mitochondria could be a potential 
contributor to CVD development through the regulation of platelet function.
Histone, proteins that structure DNA into units known as nucleosomes, can be modified at 
their amino-acid tails. Histone modifications refer to the post-translational alterations of the 
N-termini of these tails that subsequently modify histone-DNA interactions [7]. Acetylation 
is a major type of histone modification involving the addition or removal of an acetyl group. 
This process is catalysed by proteins known as histone acetyltransferases (HATs) and histone 
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deacetyltransferases (HDACs). This mechanism alters chromatin structure (heterochromatin 
versus euchromatin) to influence gene expression [3].
RNA-based epigenetic processes involve non-coding RNA (ncRNA) and are factors in the 
chromatin-based regulation of gene expression [8]. ncRNAs can be classified as either long 
or short. Whilst long ncRNAs are a major form of RNA-based epigenetic regulation, some 
small ncRNAs also have a function in chromatin-based silencing. For example, microRNA 
(miRNA) is a subset of ncRNA that negatively regulates gene transcription by degrading 
Figure 1. Modifiable risk factors covalently alter the static genome by processes involving epigenetic writers, erasers and 
readers, which fine-tune gene expression in an age and lifestyle dependent manner, a process known as epigenetic drift. 
The term epigenetics refers to stable patterns of gene expression and they are not dependent on dynamic changes in 
coding DNA. These gene expression states are encoded in the epigenome—a collection of chemical marks on DNA or on 
histones that are established during embryogenesis and are modified by age and environment over a person’s lifetime. 
Studies have uncovered stochastic DNA methylation drift that reflects imperfect maintenance of epigenetic marks. 
We hypothesise that drift creates epigenetic mosaicism in ageing haemopoietic stem cells in the bone marrow. This in 
turn impacts on HSC differentiation, maturation and platelet production. This may highlight platelets as a functional 
diagnostic index of cardiovascular competence. The fact that the initiation and progression of CVD is characterised 
by a lag time between onset and clinical manifestation provides a window of opportunity for the implementation of 
intervention strategies to reduce the CVD burden. In addition, such studies will better inform primary, secondary and 
tertiary preventive strategies—promoting an ageing well paradigm and optimising a person’s disease free years.
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or repressing target mRNA [9]. miRNA can control the expression of important epigenetic 
regulators such as histone deacetylases and DNA methyl-transferases and similarly, DNA 
methylation and histone modification can control the expression of some miRNA, thereby 
forming a feedback loop [10]. This complex crosstalk between miRNA and epigenetic path-
ways forms an  epigenetic-miRNA regulatory circuit, arranging the whole gene expression 
profile. Disruption of this circuit interferes with normal physiological functions and can con-
tribute to disease process.
Individuals age differently and lifestyle factors such as exercise or smoking have been shown 
to delay or accelerate the ageing process, respectively [11]. These observations have resulted 
in the search for molecular markers to predict and monitor age-associated disease. DNA 
methylation is associated with chronological age over time [12]. Epigenetic drift is the term 
given to epigenetic modifications as they occur as a direct consequence of age [13]. This was 
previously observed when DNA methylation marks in identical twins differed increasingly 
as a function of age [1]. Monozygous twins share a common genotype and while this study 
found that the twins were epigenetically synonymous during childhood, older twins showed 
significant differences in their total content and dispersal of histone acetylation and DNA 
methylation. Disparity in these epigenetic marks between twins may be as a result of lifestyle 
influences such as diet, physical activity levels, stress and smoking.
Epigenetic drift affects the majority of the genome over time leading to biological ageing 
(Figure 2). Ageing is a natural process associated with the de-regulation of histone tags, 
 senescence-associated lncRNA, a gradual de-regulation of DNA methylation, in a potential 
linear fashion depicted by age-predictive linear models [14]. However, an individual exposed 
to either environmental or genetic risk factors may show signs of premature ageing as a 
result of either lifestyle or environmental risk factors. De-regulation of DNA methylation can 
increase the susceptibility to chronic diseases like CVD. Furthermore, it has been hypoth-
esised that a healthy lifestyle may reserve a more intact epigenome, promoting longevity [15]. 
In a recent compelling study by Horvath and colleagues, a novel, sensitive and highly robust 
DNAm age estimator (based on 391 CpGs) was developed for human fibroblasts, keratino-
cytes, buccal cells, endothelial cells, lymphoblastoid cells, skin, blood and saliva samples [16]. 
This seminal research builds upon and overcomes the limitations of the two ground-breaking 
studies on the epigenetic clock (biological/molecular age) and its relationship with chrono-
logical age. These studies, one a blood-based age estimator [14] and the other a pan-tissue 
estimator [17], facilitated age estimates (DNAmAge) that are widely used in epidemiological 
studies. The novel ‘skin and blood clock’ overcomes the technical and sensitivity limitations 
of the previous DNAmAge biomarker panels.
DNA methylation undergoes extensive changes during differentiation of self-renewing stem 
cells [18, 19]. Indeed, DNA methylation is involved in the production of MKs and subsequent 
transcription. Lifestyle components such as physical inactivity and obesity may incur epi-
genetic changes in the production of platelets from megakaryocytes. Thus, platelets could 
signify a marker of megakaryocyte epigenetic drift, holding substantial predictive potential of 
disease. Epigenetic changes in the megakaryocyte genome such as hypomethylation of genes 
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determining PLT or changes in histone acetylation with aging have been suggested to play an 
important role in platelet function [20].
miRNAs are short [18–24] nucleotide long, non-coding RNAs that function in post-transcrip-
tional regulation of gene expression. They inhibit translation by binding with the 3′-untrans-
lated (UTR) regions of their target mRNA. Here, the miRNA promotes silencing of various 
genes [21, 22], hence now termed ‘fine-tuners’ of cellular phenotypes. They are thought to be 
involved in the regulation of ~60% of human genes [23, 24]. miRNA can be classed as intronic, 
exonic and intergenic miRNA, according to the location of their encoding genes [25]. Intronic 
miRNAs account for approximately 70% of all transcribed miRNA [26, 27]. Intergenic miRNAs 
are found between two protein-coding genes and employ their own promoters and regulatory 
molecules. As miRNAs target mRNA by imperfect binding, each miRNA has multiple targets, 
enabling miRNAs to regulate over half of the human genome [28]. The miRNA population 
within a cell can be highly concentrated, with tens of thousands of miRNA copies per cell. 
Figure 2. Schematic representation of ageing well versus accelerated ageing. Poor lifestyle choices such as inactivity 
and diet are rapidly becoming a global pandemic, accelerating many chronic illnesses such as cardiovascular disease, 
metabolic disorder, diabetes, Alzheimer’s disease and cancer. Understanding their pathophysiology is important for the 
development of future therapeutic interventions, stratification of clinical trials and to challenge our current perception of 
engaging with cost effective measures such as lifestyle management. The aetiology of age-related chronic illnesses involves 
a complex interplay between many biological processes and is modulated by non-modifiable and modifiable risk factors.
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They possess a long half-life (a half-life of between 28 and 220 h has been reported) and are 
very stable [29]. Turnover of mature miRNA is required for rapid changes in miRNA expres-
sion profiles. Regulation of miRNA maturation occurs during various steps throughout their 
biogenesis at both a transcriptional and post-transcriptional level [30]. Transcriptional regula-
tion involves alterations to the expression of a host gene such as epigenetic regulation (where 
miRNA genes located near CpG islands in the genome are found to be hyper-methylated). 
Post-transcriptional mechanisms define modifications in miRNA processing and stability [31].
2. Platelet Epigenetics
2.1. Platelet miRNA
Platelet function is a highly regulated process. Despite their anucleate nature, platelets accom-
modate a small but competent transcriptome that is employed for translation of various 
proteins with significant physiological functions. Platelets have been shown to retain genetic 
material derived from their megakaryocyte precursor. Approximately 32% of all human genes 
are present in platelets at the mRNA level [23]. It is well accepted that platelets contain the nec-
essary splicing machinery, rough ER and polyribosomes that allow the synthesis of proteins 
required for their functioning [32]. Perhaps due to the requirement of sustaining a proteome 
over an ~8-day life span, the fact that the average half-life of a cellular protein is 46 h, or the 
necessity to adapt to environmental stimuli, it is equitable to assume that the platelet must also 
retain its transcriptome, as well as processes of nucleated cells such as splicing, translating and 
post-transcriptional RNA mechanisms. The fact that platelets contain mRNA and are capable 
of protein synthesis has raised the issue of how these mRNAs are regulated. Notably, stored 
platelets in blood banks can synthesis integrin β3 [33]. The existence and functionality of a 
miRNA pathway in the anucleate human platelet was first described in a landmark study by 
Landry and co-workers [34], who showed by locked nucleic acid (LNA) microarray profiling, 
that platelets harboured an impressive number (219) of miRNA. Further analysis discovered 
the presence of functional processing miRNA machinery in platelets—Dicer and Ago2— 
suggesting that partial biogenesis of mature miRNA from pre-miRNA could occur within 
platelets themselves [34, 35] as pre-miRNAs have been identified at low levels (21 transcripts) 
in platelets [23]. Star or passenger strand miRNA have also been identified [36]. Accordingly, 
the detection of nuclear miRNA microprocessor Drosha and DGCR8 in platelets has not been 
observed, consistent with their anucleate nature. Moreover, miRNA-associated Ago2 com-
plexes were identified, in addition to the presence of P2Y
12
 in Ago2 precipitates, suggesting a 
regulation of P2Y
12
 by miRNAs [34].
The next breakthrough study in platelet miRNA biology revealed that a protein involved 
in platelet granule release, platelet vesicle-associated membrane protein 8 (VAMP8), was 
associated with distinctly different platelet aggregation responses to epinephrine in healthy 
donors, and that VAMP8 was regulated by miR-86 [37]. Since then, the platelet miRNA field 
has grown exponentially, whereby a number of studies have suggested a physiological role 
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for miRNA in the regulation of platelet function. Most notably, research by Nagalla et al. [38], 
who focused on the roles of miRNA as biomarkers of platelet reactivity and controllers of 
platelet mRNA disparity, demonstrated that miRNA profiles of healthy subjects (n = 19) were 
associated with the response of platelet aggregation to epinephrine [38]. They also employed 
a computational approach to produce possible miRNA-mRNA pairs (miR-200b: PRKAR2B, 
miR-495: KLHL5 and miR-107: CLOCK), pairings which were experimentally validated in cell 
lines. Networks of miRNA-mRNA pairs also associated with age, gender and race [39, 40]. 
Other reports on agonist-induced platelet activation by thrombin (and ADP) show differential 
expression of platelet miRNA compared to resting platelets [41].
Progression in miRNA detection techniques has led to the revelation of 40 new miRNA 
sequences, expanding the total amount of platelet expressed miRNAs to more than twice that 
(544) of the initial finding [23, 35, 42]. Transcriptomic approaches show that miRNA make 
up the majority (80%) of all small RNAs in platelets. Furthermore, comparison of RNA and 
miRNA by cell type showed that despite low RNA yields, platelets express high quantities of 
miRNA compared to their nucleated counterparts.
A number of highly expressed miRNA have been characterised in human platelets, some of 
which are involved in myeloid cell differentiation, megakaryocytopoiesis and thrombopoi-
esis. miR-223 has been identified as the most highly expressed platelet miRNA [38, 43, 44] 
and has roles in thrombopoiesis and megakaryocyte differentiation [24]. miR-223 regulates 
ADP P2Y
12
, a target for existing anti-platelet drug therapy. The 3′-UTR of P2Y
12
 mRNA has 
been identified as complementary to the miR-223 seed region. Platelet miR-223 has also been 
observed to be decreased in subjects who show high levels of platelet activation whilst on 
clopidogrel therapy. Furthermore, miR-223-deficient mice show reduced bleeding times, 
larger thrombi and elevated sensitivity to low doses of thrombin, suggesting an important 
role of miR-223 in modulating platelet function [45]. miR-126 plays central roles in vascular 
inflammation and is thought to be the second most highly expressed miRNA in platelets [46]. 
miR-126 was found to correlate with circulating P-Selectin levels in T2DM subjects and this 
level was sensitive to aspirin treatment, signifying a platelet origin. miR-126 is postulated to 
regulate ADAM9 and P2Y
12
 receptor expression in platelets and inhibition of miR-126 in mice 
distinctly reduces platelet aggregation [47].
Existence of miRNA in platelets is multifaceted. Besides their obvious function as regulators of 
platelet protein expression, platelet miRNAs have been labelled as biomarkers of disease and 
platelet activation, markers of mature megakaryocyte miRNA and as a means of understanding 
megakaryocyte/platelet gene expression [48]. The majority of platelet miRNA are supposedly 
formed in the megakaryocyte and packaged into platelets upon formation. For example, miR-
146b positively regulates megakaryopoieses by targeting and down regulating the megakaryo-
poieses inhibitor PDGFRA [49, 50]. miR-142 has also been reported to inhibit megakaryocyte 
production. In miR-142 knockout mice, platelet counts are decreased and MK differentiation is 
modified, including reduced proplatelet network establishment [51]. The total extent to which 
MK and platelet mature miRNA patterns correlate remains an area of active investigation. A sig-
nificant correlation between the miRNA levels was found using three separate studies [34, 52, 53].
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Perhaps, the most intriguing feature regarding platelet miRNA is their extracellular function. 
miRNA can be packaged and delivered to distant cells in the form of platelet microvesicles 
(PMV) and/or microparticles (PMP), fulfilling novel processes of gene regulation in target cells 
[54]. Initial studies by Laffont and Gidlöf demonstrated the functionality of platelet miRNA 
[24, 55]. Functional complexes of miR-223 and Argonaute 2 protein (Ago2) packaged in MVs 
from activated platelets were found to modulate the expression of targeted endothelial cell 
endogenous mRNA transcripts FBXW7 and EFNA1. This miR-223/Ago2 complex has also 
been shown to reduce expression levels of insulin-like growth factor 1 receptor in endothelial 
cells, and to promote human umbilical vein endothelial cell (HUVEC) apoptosis [56].
Gidlof et al. suggested that platelet miRNA could modulate vascular endothelial inflamma-
tory responses [55]. They described a down regulation of intercellular adhesion molecule 1 
(ICAM-1) gene expression in cultured human microvascular endothelial cells after exposure 
to miR-320b, which is secreted upon platelet activation and reduced in platelet thrombi aspi-
rated from patients with ST-segment elevation myocardial infarction (STEMI). The relevance 
of this intercellular transfer was further reinforced when Liang et al., showed that platelet-
released miR-223 through platelet MPs can encourage lung cancer cell invasion by targeting 
the tumour suppressor EPB41L3 [57].
Novel research has shown that platelet MPs containing miRNA can also be internalised by 
primary human macrophages and deliver functional miR-126-3p. miR-126-3p caused a down-
regulation in the expression of four predicted mRNA targets of miR-126-3p and a reduction in 
macrophage cytokine release. This suggests that platelet miRNA-containing MPs can modify 
the macrophage transcriptome and potentially reprogram their function [58]. Finally, platelet-
derived exosomes have recently been shown to carry miR-223, miR-339 and miR-21, which 
can be transferred to SMCs affecting PDGRFβ [13].
2.2. Platelets, lifestyle and miRNA in the aetiology of CVD
Efforts in coping with CVD require further understanding of its aetiology in order to develop 
effective management strategies. Epidemiological studies in adults have acknowledged a set 
of characteristic risk factors that predict the probability of a person developing clinical mani-
festations of disease [59, 60]. CVD risk factors are classed as modifiable or non-modifiable. 
Non-modifiable risk factors include age, ethnicity, gender and family history. Modifiable risk 
factors include hypertension, smoking, diabetes, unhealthy diet, cholesterol, physical inactiv-
ity (PI, sedentary lifestyle and low cardiorespiratory fitness) and overweight/obesity. Risk fac-
tors for CVD track from childhood into adulthood [61] and are strong predictors of subclinical 
atherosclerosis in early adulthood. The majority of CVD is caused by modifiable risk factors 
and up to 80% of CVD may be prevented if risk factors are avoided [62]. Physical inactivity and 
obesity are primary potent risk factors, both of which can severely impact platelet physiology.
Platelets have central roles in CVD [63] contributing to both early stages of endothelial dys-
function and advanced stages of the plaque rupture [64]. Platelets participate in early stage 
disease initiation through multiple mechanisms enabling adhesion to dysfunctional endothe-
lium. Activated platelets express high levels of adhesion receptors (e.g., ICAM1, P-Selectin, 
CD40L) associated with oxidised-LDL (ox-LDL) that contributes to vascular inflammation 
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[65]. TLR signalling may also play a role in the progression of atherosclerosis by binding 
of lipopolysaccharides (LPS) to TLR4 on platelets and also mediating platelet-neutrophil 
interactions.
Direct cell-cell communication through platelet P-Selectin and CD40 ligand (CD40L) encour-
ages inflammatory processes [66]. CD40L is thought to be at the heart of the atherosclerotic 
process, with 90% of circulating CD40L residing in platelets. CD40L is sent to the platelet 
surface upon activation, where it can initiate numerous inflammatory processes. The release 
of CD40L is intrinsically linked to αIIbβ3 as αIIbβ3 antagonists can block the release of sCD40L 
from activated platelets in vitro. Recently, platelet CD40 was shown to mediate the formation 
of platelet-leukocyte aggregates (stimulates leukocyte activation) and release inflammatory 
chemokines that activate endothelial cells, supporting atherosclerosis [66]. The significance of 
P-Selectin in atherosclerosis has been demonstrated in P-Selectin deficient animals that were 
protected from the disease. The role of platelet P-Selectin was clarified further by Huo et al., 
who illustrated that the introduction of P-Selectin expressing platelets into ApoE (−/−) mice 
accelerated atherosclerosis, whereas mice injected with platelets lacking P-Selectin formed 
smaller plaques [67].
Platelet-derived microparticles released upon activation may further amplify the progression 
of atherosclerosis through processes of adhesion, coagulation, inflammation and lipid metabo-
lism [68]. Platelets also provide a huge repertoire of additional inflammatory mediators includ-
ing a vast array of chemokines and cytokines that contribute to the crosstalk of platelets with 
other inflammatory cells—e.g., endothelial cells, monocytes, neutrophils, dendritic cells and 
T-cells [66]. The major function of platelets in atherosclerosis is the recruitment of leukocytes 
through direct receptor-ligand interactions or amplification of leukocyte recruitment through 
chemokine release. This bidirectional relationship is extremely important as platelets encour-
age leukocyte differentiation into a pro-adhesive and pro-migratory phenotype, and the leuko-
cytes secrete mediators that reciprocally activate platelets.
Following atherosclerotic plaque rupture in severe CVD states, the exposure of thrombo-
genic substrates to circulating platelets instantly triggers platelet adhesion, activation and 
aggregation, forming a prothrombotic surface and subsequently encouraging thrombosis, 
vasoconstriction and vascular occlusion. Activated platelets expose phospholipids on their 
surface, which also promotes the coagulation cascade and subsequent fibrin production [64]. 
Given the critical roles of platelets in the pathogenesis of atherosclerosis and the development 
of acute thrombotic events, anti-platelet therapy has been widely employed in the primary 
and secondary prevention of CVD. Some of the current anti-platelet therapy drugs include 
Aspirin, which irreversibly inhibits cyclooxygenase to subsequently decrease TxA
2
 produc-
tion and limit platelet aggregation. Clopidogrel and Prasugrel are examples of P2Y
12
 recep-
tor antagonists that inhibit the soluble agonist ADP, whilst Tirofiban and Abciximab block 
αIIbβ3-ligand interactions. Other anti-platelet therapies include thrombin and phosphodies-
terase inhibitors (block degradation of cyclic nucleotides) [69, 70].
Given the impact of miRNA gene regulation, it is unsurprising that the dysregulation of miRNA 
is implicated in CVD. miRNAs are central players in modulating gene expression of cells/plate-
lets collectively involved in CVD, and mediate inflammation, lipid uptake and cell differentiation 
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in atherosclerosis. Platelet miRNA signatures (miR-25-3p, miR-221-3p and miR-374b-5) alter 
between patients with ST-segment elevation myocardial infarction (STEMI) and those with non-
STEMI [71] suggesting that levels of platelet miRNA could impact platelet thrombogenicity and 
type of infarction. Furthermore, circulating miRNAs associated with the risk of MI (miR-126, 
miR-150, miR-223 and miR-197) are abundantly expressed in platelets. Platelet miRNA are impli-
cated in premature CAD as two miRNAs in platelets are up-regulated in patients compared to 
controls (miR-340* and miR-624*), although whether or not they are the cause or consequence 
is currently unknown [72]. Besides their roles as mediators and biomarkers of CVD, platelet 
miRNA act as novel surrogate measures of the responsiveness to anti-platelet therapies used 
in CVD [73]. miR-223 levels are significantly down regulated in low responders to anti-platelet 
therapy [45, 74]. Furthermore, expression of platelet miR-26a has been linked with clopidogrel 
resistance during coronary stenting [75]. This theory is strengthened by research demonstrating 
how the switch from dual anti-platelet treatment with clopidogrel to ticagrelor is linked with 
significant changes in the level of platelet-specific circulating miRNAs, namely miR-223, miR-
126 and miR-150 and miR-96 [76]. Other research investigating the effects of anti-platelet therapy 
on platelet miRNA levels showed that in vitro platelet activation resulted in transfer of miR-126 
from platelets to plasma, whereas in aspirin-treated platelets, this process was not observed. In 
vivo, aspirin intake resulted in platelet inhibition and lower circulating platelet-derived miR-126 
levels than were seen in untreated subjects [77]. Greater understanding of the meaning of plate-
let miRNA in CVD patients could aid in the diagnosis and treatment of these diseases.
2.3. Effect of obesity on platelet function
Obesity is a multifactorial condition involving a plethora of interrelated processes such as 
alterations in lipid metabolism, insulin resistance, inflammation, endothelial dysfunction, adi-
pokine imbalance and oxidative stress. These metabolic aberrations have been postulated to 
be involved in platelet hyper-aggregability. Indeed, platelet activation markers are described 
as elevated in obesity, contributing to the inflammatory and prothrombotic state [78]. Subjects 
with overweight and obesity display increased platelet activation markers urinary-11-de-
hydro-TXB2 [79], MPV [80] and PLT [81]. Greater platelet activation (P-Selectin and PMP) is 
also linked to central arterial stiffness and carotid wall thickness amongst other atherosclerotic 
risk factors in overweight and obese subjects [82, 83]. The major mechanisms behind platelet 
function in obesity include a reduced sensitivity to insulin and resistance to their main inhibi-
tory mediators PGI
2
 and NO, elevated oxidative stress and an altered intracellular environ-
ment with increased cytosolic Ca2+ [84]. Platelets have insulin receptors which impact platelet 
function by regulating platelet response and sensitisation of platelets to inhibitory mechanism 
of PGI
2
 and NO. In obese subjects, the anti-aggregating effect of insulin is diminished [85, 86].
Elevated oxidative stress also plays important roles in obesity-related platelet dysfunction. 
Oxidative stress results from an imbalance between the generation of free radicals and anti-
oxidant enzymes [87]. High reactive oxygen species (ROS) generation by excess adipose tis-
sue reduces NO bioavailability, enhancing surface expression of adhesion molecules, and 
enabling platelet activation and adhesion. Increased ROS also converts arachidonic acid into 
F
2
-isoprostanes such as 8-iso-PGF
2α
 that can modulate platelet adhesive function [88]. Activated 
platelets also produce ROS [89], amplifying their own aggregatory potential by increasing 
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αIIbβ3 and CD40L expression [90, 91] and stimulating intraplatelet F
2
-isoprostanes produc-
tion. Both decreased NO synthesis and bioavailability from ECs and platelets contribute to 
the pathogenesis of obesity, likely promoting thrombosis. Research by Leite et al. describes a 
decrease of nitric oxide synthase (NOS) activity and cGMP levels with simultaneous platelet 
hyper-aggregability in obese subjects compared to healthy controls with impaired antioxidant 
responses as potential contributors [92]. Anfossi et al. showed that platelet sensitivity to anti-
aggregatory effects of PGI
2
 and NO is reduced in obesity [84]. Importantly, weight loss in 
obese subjects marks a reduction in platelet activation markers and can potentially reverse the 
platelet responsiveness to NO and prostacyclin [93, 94]. A 10% weight reduction in obese sub-
jects resulted in significant reductions in BMI, endothelial dysfunction and platelet aggrega-
tion. The changes in platelet function were associated with improvement in insulin sensitivity, 
indicating a tight relationship between the two. Weight loss also resulted in reduction in lipid 
peroxidation markers [95] and P-Selectin expression in overweight CAD patients [96].
Although an association between obesity and platelet activation is evident, the molecular 
mechanisms responsible have only begun to surface [97]. Platelet RNA is reflective of patho-
logical disease states where inflammatory transcript profiles (e.g., INFG, IL1R1, IL6 and TLR2) 
correlate significantly with increasing BMI [98], supporting the hypothesis that surplus fat 
could unfavourably alter the inflammatory potential of platelets. However, obesity can also 
cause dysregulation of other factors that control haemostasis such as microRNA (miRNA). 
There is increasing evidence to show that miRNA is involved in the pathogenesis of obesity 
[99], where plasma levels of miR-223 are reduced in obese compared to lean subjects, sug-
gesting that the miR-223/P2Y
12
 alliance could signify a contributing mechanism of platelet 
activation in obesity [36].
2.4. Role of physical activity on platelet function
Those who engage in regular physical activity or exercise have a reduced prevalence of 
CVD. PA has been extensively studied due to its beneficial effects on all-cause mortality. 
Evidence to support the inverse relationship between PA and either CVD, cancer or depres-
sion continues to accumulate. With regard to CVD, regular PA/exercise reduces blood 
pressure, serum triglycerides, total body fat and visceral fat and LDL cholesterol [100]. 
Differences in these known factors have been demonstrated to explain a large proportion 
of the inverse relationship between physical activity and CVD risk [101, 102]. However, 
over 40% of the inverse association remains unexplained. Although the beneficial effects of 
regular exercise on blood lipids and blood pressure have been well documented, research 
focusing on platelet function has only recently gained greater attention. Since platelets play 
a key role in the pathogenesis of CVD, the protective effect of exercise against CVD may be 
partially due to alterations of platelet function [103].
Aerobic fitness is measured by maximal oxygen uptake (VO
2
 max) during incremental exer-
cise and is globally acknowledged as the best assessment of cardiovascular fitness [104]. VO
2
 
max represents the maximal amount of oxygen that an individual can take in and use to pro-
duce energy. VO
2
 max is a function of the ability of the cardiovascular system to deliver blood 
and oxygen to skeletal muscle, and the ability of skeletal muscle to extract this oxygen and 
use it to produce energy. Exercise effects on platelet function in both diseased and healthy 
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populations have elicited profound interest in the last decade. The majority of research sur-
rounding platelet function and physical activity/exercise has focused on acute (single bout) 
aerobic exercise. Potential effects of acute exercise on platelet function (mainly aggregation) 
have been investigated through various studies in adult subjects with varying intra- and 
inter-individual results, making interpretation problematic. Differences in population type 
(e.g., CVD versus healthy), methods employed to assess platelet function and techniques to 
examine reactivity are the main reasons for discrepancies and lack of consistency between 
research groups [105]. Different platelet adhesion experimental protocols have provided 
no definitive consensus on the platelet response to acute exercise in healthy adult subjects 
[106–110]. High levels of plasma fibrinogen after exercise result in elevated blood viscosity 
and this along with increased vWF binding, αIIbβ3 and P-Selectin expression all contribute to 
the increased platelet aggregation after acute exercise [111]. In general, it appears that acute 
vigorous exercise induces a hyper-reactive haemostatic state [112] and a transient increase in 
agonist-induced platelet adhesion and aggregation in vitro and ex vivo. However, there is no 
definitive consensus regarding the short-term effects of exercise on platelet function.
Cardiorespiratory fitness (CRF) is the ability to perform large muscle, moderate to high inten-
sity exercise for prolonged periods and depends on the respiratory, cardiovascular and skel-
etal systems. CRF represents the adaptation to long-term exercise. High CRF levels are also 
linked with reduced CVD risk factors such as hypertension, obesity in the general population 
and CVD patients [113–116]. CRF was first postulated as a significant determinant for changes 
in platelet function in response to acute exercise after observations that acute strenuous exer-
cise increased platelet activation in sedentary, but not physically active, subjects [106, 117]. 
The actual relationship between CRF and platelet function has been referred to in a recent break-
through study by Heber et al., who investigated platelet function and CRF in 62 young women 
[118]. Platelet function was assessed by determination of P-Selectin and CD40L expression and 
quantification of platelet ROS generation in platelet-rich plasma (PRP). Basal platelet activation 
(reflected by CD62P expression) and agonist-induced platelet activation (ROS, CD62P and CD40L) 
were higher in the LF compared to the MF and HF. The group found no difference between basal 
CD40L expressions (non-agonist induced). Interestingly, basal platelet function in the MF and HF 
were almost equal, indicating a definite influence of CRF on platelet function. A high CRF level 
is a result of exercise training and habitual physical activity. Therefore, research on the effects of 
longitudinal exercise training on platelet function has mainly shown that habitual exercise has 
favourable effects on platelet function. Eight weeks of exercise training (60% VO
2
 max 5×/week 
30 min/day), reduced shear stress-induced platelet activation and ox-LDL-potentiated platelet 
function [109, 111]. Importantly, after 12 weeks of de-conditioning, the beneficial effects of exer-
cise on platelets were non-existent and platelet function returned to its pre-training state.
De Meirelles et al. reported that chronic physical activity had favourable effects on platelet 
activation in hypertensive patients at rest [119]. Twelve weeks of regular exercise (75–85% 
VO
2
 max 5×/week for 45–60 min) reduced platelet aggregation in response to collagen. Santilli 
et al. investigated the effects of regular high intensity (60–75%) aerobic exercise for 2 months 
in low and intermediate CVD risk sedentary subjects [120]. Exercise training was associated 
with reductions in TxA
2
, plasma P-Selectin and platelet-derived CD40L, despite no reduction 
in CRP (representing systemic inflammation). Evidently, physical activity and exercise affects 
nearly all facets of platelet function [121]. Studies on the effects of acute exercise appear to 
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heighten platelet reactivity. Regular exercise can improve this response, seems to have an anti-
thrombotic effect on platelets and could represent a portion of the protective effects of exercise 
on CVD risk factors. Moreover, effects of exercise are not maintained with cessation of train-
ing. Of importance, all of these studies discussed were performed in adults and not adoles-
cents when the CVD risk factors and atherosclerotic process has begun. Platelet function and 
exercise in children or adolescents is in its infancy, an area that requires urgent research [122].
2.5. Role of physical inactivity and sedentary lifestyle on platelet function
In contrast to physical activity, physical inactivity/sedentary behaviour is a universal leading 
cause of death and independent CVD risk factor [123, 124]. Sedentary behaviour refers to any 
waking activity characterised by an energy expenditure ≤1.5 metabolic equivalents in a sitting or 
reclining posture [125]. However, in contrast to the evidence supporting the benefits of acute and 
chronic exercise, relatively little is understood about the mechanisms underlying the physiologi-
cal, cellular and molecular responses to physical inactivity. Incomplete understanding of this 
relationship is a huge barrier to combating the development of CVD and its ancillary risk factors. 
Our knowledge of physical inactivity is somewhat indirect and is mainly based on the positive 
effects of exercise training on the sedentary population. As a sedentary lifestyle is often associ-
ated with obesity [126], some mechanisms involved in the pathogenesis of physical inactivity are 
similar to that of obesity such as insulin resistance [127], hypertension and increased inflamma-
tion [128]. However, distinct factors associated with sedentary behaviour include reduced mus-
cular activity of lower extremities, decreased blood flow and reduction of shear stress, which 
increases oxidative stress, endothelial dysfunction [129] and arterial remodelling [130, 131].
2.5.1. Physical activity/inactivity-specific miRNA
The plasticity of platelets and other blood cells is vital for responding to environmental changes 
in response to physical (in)activity patterns. However, the molecular factors influencing plate-
let function/response/adaptation to physical (in)activity remain poorly understood. Recently 
identified miRNAs have gained attention as modulators of platelet function [34]. Evidence for 
miRNA involvement in exercise-associated gene expression changes in a number of cell types 
including peripheral blood mononuclear cell, neutrophil and skeletal muscle in non-trained and 
trained subjects has been illustrated [132–134]. Work by Baggish et al. showed altered expres-
sion of circulating miRNA (c-miRNA) in response to acute and chronic exercise in athletes [135]. 
Eight c-miRNA involved in cellular processes related to exercise adaptation (muscle contractility, 
inflammation, and angiogenesis) were examined. They observed four distinctive signatures of 
c-miRNA; c-miRNA up-regulated by acute exhaustive exercise pre- and post-exercise interven-
tion, c-miRNA responsive to acute exercise pre- but not post-intervention, c-miRNA only respon-
sive to exercise intervention and non-responsive miRNA. Moreover, evidence of these physical 
activity-specific microRNA signatures [136–138] has ingrained concepts of physical inactivity-
specific miRNA profiles. Epigenetic variation could therefore be a potential mechanism allow-
ing for independent or synergistic effects of physical inactivity on platelet function. Hibler et al. 
recently described indications for epigenetic variation (by miRNA expression) as a link between 
physical activity and sedentary lifestyle [139]. An epigenetic adaptation to habitual exercise has 
been described [140, 141]. Similarly, an epigenetic adaptation to physical inactivity may exist.
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2.6. Physical activity/inactivity and platelet epigenetic drift
It has been well recognised that regular exercise may reduce risk of major vascular thrombotic 
events and protect against CVD [123]. Differences in known factors explain a large percentage 
of the inverse relationship between physical activity and CVD risk [101, 102]. Nevertheless, over 
40% of the inverse association remains unexplained. Although the beneficial effects of regular 
exercise on blood lipids and blood pressure have been well accepted, research focusing on plate-
let function has only recently gained greater attention. Whilst it is known that platelet function 
and platelet indices (markers of platelet activation) are altered in pathological states such as CVD, 
only a minority of studies have solely examined the relationship between overall physiological 
health and platelet function in healthy subjects [120, 142]. Therefore, it is imperative that future 
studies explore the feasibility of platelet indices and whole blood platelet function measurements, 
as useful, non-invasive initial biomarkers of early/subclinical CVD risk and lifestyle parameters.
Low cardiorespiratory fitness is associated with physical inactivity [143]. This has major health 
effects globally, with approximately 3.2 million deaths each year attributable to inadequate physical 
activity. Evidence has shown that physical inactivity and sedentary behaviour have direct effects on 
CVD risk factors [144]. Moreover, in contrast to the accumulating evidence supporting the benefits 
of regular exercise, relatively little is understood about the deleterious mechanisms underlying the 
physiological, cellular and molecular responses to PI, specifically with regard to platelet function.
3. Future research avenues
Our group, in collaboration with the European Space Agency (ESA), the Centre National 
d’Etudes Spatiales (CNES) and MEDES (Institute for Space Medicine and Physiology, Toulouse, 
France) have employed ground-based models of microgravity, i.e., dry water immersion (DI) 
to study the effects of spaceflight on human physiology in a precisely controlled environment. 
DI involves immersing a subject in a bath of thermoneutral water covered by a waterproof 
fabric [145]. Several factors act simultaneously on the human body during immersion, includ-
ing hydrostatic compression, supportlessness and extensive physical inactivity. Hypokinesia 
and hypodynamia are the major characteristics of physical inactivity induced by dry immer-
sion. Hypodynamia involves a reduction in postural muscle load, whereas hypokinesia is a 
decline in motor activity. For these reasons, DI has been well accepted as a valuable tool to 
study physical inactivity [146]. DI presents a unique opportunity to analyse the specific effects 
of physical inactivity on platelet physiology/function and related biomarkers.
Recent studies reflect the first comprehensive attempts to evaluate the relationship between 
platelet function and physical activity, physical inactivity and overweight. While exploratory 
in nature to date, several questions remain unanswered and so further studies are warranted. 
The search for simple biomarkers that allow for early identification of subclinical/CVD risk 
is ongoing. Platelets can reflect changes in unhealthy lifestyle patterns. The Impact-R test is a 
relatively inexpensive test that can reliably detect changes in platelet adhesion and could be 
employed for CVD risk evaluation amongst subjects who are asymptomatic. Platelet indices 
and function markers should be further tested in larger populations to determine their reli-
ability as surrogate markers for evaluating physiological health and to test during either phar-
macological and lifestyle interventions. A relatively low dose of exercise has been shown to be 
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sufficient to normalise platelet function in low fit females [118]. Larger studies incorporating 
exercise interventions at low doses over a lengthy period of time and examining more extensive 
aspects of platelet function in low fit subjects would develop this knowledge. The prescription 
of anti-platelet therapy is frequently used to treat CVD patients. However, the other residual 
risks (oxidative stress, inflammation etc.), which occur due to associations between CVD risk 
factors, are not eliminated efficiently by these therapies. In this sense, physical activity has been 
emphasised as it promotes favourable physiological adaptations, which may attenuate the car-
diovascular risk factors and residual risks. Regular exercise may also impact platelet function 
in CVD patients. Exercise interventions in these populations could be beneficial in terms of 
reducing anti-platelet therapy dosage or combining anti-platelet therapy with exercise [147], 
i.e., prescriptive exercise medicine as an adjuvant management strategy/therapy.
The investigation of epigenetic processes is almost a completely unexplored area in plate-
let biology as analyses of these mechanisms require DNA [2]. Platelets have functionally 
active mitochondria [148]. Like nuclear DNA, mitochondrial DNA (mtDNA) can also be 
methylated, moderating control of mitochondrial gene expression. Understanding epigen-
etic regulation of mitochondrial genes in platelets is proving crucial to understanding their 
implication in CVD development [6]. Furthermore, miRNA have recently been linked with 
platelet mitochondrial health in stored platelets [149]. Platelets contain the machinery to 
process pre-miRNA to mature miRNA [34]. Platelets contain higher levels of pre-miRNA 
than other blood cells [56], and the maturation of pre-miRNA could contributed to altered 
miRNA profiles due to physical activity and inactivity. This may represent a more focused 
and efficient method of monitoring platelet function. Targeting levels of other biogenesis 
molecules in the miRNA pathway would also be an interesting avenue of platelet miRNA 
biology. Recently, Elgheznawy et al. showed that Dicer was decreased in patients with 
TD2M compared to healthy controls, whereas interestingly, Argonaute 2 levels did not dif-
fer [150]. Experiments investigating levels of miRNA processing machinery such as Dicer 
and Argonaute 2 in physically active and sedentary populations would be of major interest.
Long-term lifestyle choices such as physical inactivity may incur epigenetic penalties in 
megakaryocytes, and in the biological processes of megakaryocytopoiesis and thrombopoiesis. 
Thus, platelet miRNA could reflect these epigenetic changes, holding substantial predictive 
potential of both health and disease. Epigenetic changes in the megakaryocyte genome such 
as methylation of genes determining platelet biogenesis or changes in histone acetylation with 
aging have been suggested to play an important role in platelet function [20]. Prescribed exer-
cise could induce epigenetic changes in megakaryocytes to produce a healthier phenotype of 
platelets with a direct change in platelet reactivity.
4. Conclusion
It is evident that lifestyle factors such as physical activity, physical inactivity and overweight 
do impact platelet function. Platelets are indeed reflective of physiological and lifestyle 
changes, making them sensitive biomarkers of human health. Platelets represent a tangible 
link to physiological and pathological changes within the body. Future research in this area, 
will no doubt contribute to a greater mechanistic understanding of the relationship between 
epigenetics, cardiovascular health, lifestyle factors and platelet biology.
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